O'Shannessy Daniel J, Somers Elizabeth B, Chandrasekaran Lakshmi K, Nicolaides Nicholas C, Bordeaux Jennifer, Gustavson Mark D
Department of Translational Medicine and Diagnostics, Morphotek Inc., Exton, PA.
HistoRx Inc. (A subsidiary of Genoptix Medical Laboratory, Inc.), Carlsbad, CA.
Oncotarget. 2014 Jun 30;5(12):3983-95. doi: 10.18632/oncotarget.2108.
Tumor survival is influenced by interactions between tumor cells and the stromal microenvironment. One example is Endosialin (Tumor Endothelial Marker-1 (TEM-1) or CD248), which is expressed primarily by cells of mesenchymal origin and some tumor cells. The expression, as a function of architectural masking, of TEM-1 and its pathway-associated proteins was quantified and examined for association with five-year disease-specific survival on a colorectal cancer (CRC) cohort divided into training (n=330) and validation (n=164) sets. Although stromal expression of TEM-1 had prognostic value, a more significant prognostic signature was obtained through linear combination of five compartment-specific expression scores (TEM-1 Stroma, TEM-1 Tumor Vessel, HIF2α Stromal Vessel, Collagen IV Tumor, and Fibronectin Stroma). This resulted in a single continuous risk score (TAPPS: TEM-1 Associated Pathway Prognostic Signature) which was significantly associated with decreased survival on both the training set [HR=1.76 (95%CI: 1.44-2.15); p<0.001] and validation set [HR=1.38 (95%CI: 1.02-1.88); p=0.04]. Importantly, since prognosis is a critical clinical question in Stage II patients, the TAPPS score also significantly predicted survival in the Stage II patient (n=126) cohort [HR=1.75 (95%CI: 1.22-2.52); p=0.002] suggesting the potential of using the TAPPS score to assess overall risk in CRC patients, and specifically in Stage II patients.
肿瘤的存活受到肿瘤细胞与基质微环境之间相互作用的影响。一个例子是内唾液酸酶(肿瘤内皮标志物-1(TEM-1)或CD248),它主要由间充质来源的细胞和一些肿瘤细胞表达。在一个分为训练集(n = 330)和验证集(n = 164)的结直肠癌(CRC)队列中,对TEM-1及其通路相关蛋白的表达(作为结构掩盖的函数)进行了定量,并检查了其与五年疾病特异性生存率的关联。尽管TEM-1的基质表达具有预后价值,但通过五个特定区域表达评分(TEM-1基质、TEM-1肿瘤血管、HIF2α基质血管、IV型胶原肿瘤和纤连蛋白基质)的线性组合获得了更显著的预后特征。这产生了一个单一的连续风险评分(TAPPS:TEM-1相关通路预后特征),该评分在训练集[HR = 1.76(95%CI:1.44 - 2.15);p < 0.001]和验证集[HR = 1.38(95%CI:1.02 - 1.88);p = 0.04]中均与生存率降低显著相关。重要的是,由于预后是II期患者的关键临床问题,TAPPS评分在II期患者(n = 126)队列中也显著预测了生存率[HR = 1.75(95%CI:1.22 - 2.52);p = 0.002],这表明使用TAPPS评分评估CRC患者,特别是II期患者的总体风险具有潜力。